Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.43 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.43 |
| ▸ | CDA | P32320 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | PYGB | P11216 | 6/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301532 | 1.00 | LGALS1 (0.43) | LGALS1LGALS3LGALS9LGALS8CDA | |
| SCHEMBL7151021 | 1.00 | LGALS1 (0.43) | LGALS1LGALS3LGALS9LGALS8CDA | |
| SCHEMBL15011450 | 1.00 | LGALS1 (0.43) | LGALS1LGALS3LGALS9LGALS8CDA | |
| SCHEMBL5490736 | 0.98 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| SCHEMBL15382611 | 0.98 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Water SCHEMBL29046820 | 0.98 | LGALS1 (0.42) | LGALS1LGALS3LGALS9LGALS8CDA | |
| SCHEMBL17993201 | 0.98 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| SCHEMBL1035317 | 0.98 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| SCHEMBL22902769 | 0.98 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| SCHEMBL29055419 | 0.98 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025007274-A1 | CONJUGATE, AND INTERMEDIATE COMPOUND AND USE THEREOF | 成都先导药物开发股份有限公司 | 2025-01-09 | — | — | WO | claimed |
| WO-2024114776-A1 | BICYCLIC ABASIC NUCLEIC ACID ANALOGS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | 上海舶望制药有限公司 | 2024-06-06 | — | — | WO | claimed |
| WO-2025087290-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | 苏州瑞博生物技术股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| WO-2025031444-A1 | SIRNA FOR INHIBITING DGAT2 GENE EXPRESSION, SIRNA CONJUGATE OR PRODRUG AND PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 北京福元医药股份有限公司 | 2025-02-13 | — | — | WO | disclosed |
| WO-2025016210-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USES THEREOF | 复旦大学 | 2025-01-23 | — | — | WO | disclosed |
| WO-2025007274-A1 | CONJUGATE, AND INTERMEDIATE COMPOUND AND USE THEREOF | 成都先导药物开发股份有限公司 | 2025-01-09 | — | — | WO | disclosed |
| WO-2024208249-A1 | NUCLEOSIDE ANALOG FOR 5'-PHOSPHONATE MODIFICATION AND OLIGONUCLEOTIDE PREPARED THEREFROM | 上海舶望制药有限公司 | 2024-10-10 | — | — | WO | disclosed |
| US-20240325428-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2024-10-03 | — | — | US | disclosed |
| WO-2024188173-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE COMPRISING SAME, AND USE THEREOF | 苏州瑞博生物技术股份有限公司 | 2024-09-19 | — | — | WO | disclosed |
| US-20240309378-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE CONTAINING DOUBLE-STRANDED OLIGONUCLEOTIDE, AND PREPARATION METHODS AND USES | Suzhou Ribo Life Science Co., Ltd. (CN) | 2024-09-19 | — | — | US | disclosed |
| WO-2024188174-A1 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | 苏州瑞博生物技术股份有限公司 | 2024-09-19 | — | — | WO | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325428-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, AND PREPARATION METHOD AND USE | APOB, APOL1, RNGTT | LGALS1 3696/4885LGALS3 1785/4885LGALS9 3079/4885 |
| US-20240309378-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE CONTAINING DOUBLE-STRANDED OLIGONUCLEOTIDE, AND PREPARATION METHODS AND USES | RNGTT, NSUN2, RPRD2 | LGALS1 4776/4885LGALS3 4724/4885LGALS9 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.